Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Endocrine. 2019 Jan 28;64(1):97–108. doi: 10.1007/s12020-019-01848-6

Table 2.

Molecular profile of O-NI-EFVPTC.

Case genotyped RAS and BRAF Other mutations Copy number alteration Mitochondrial DNA mutation
1 NRAS p.Q61K GLI p.E316Q - MT-CO1 nonsense mutation G6930A MT-ND5 missense mutation T12569C
2 NRAS p.Q61R - - -
3 KRAS p.G12D AURKA p.L159fs Loss in part of 9 MT-3’flank T12228C TS2
4 KRAS p.Q61R - Loss in 21 MT-TL1 5’ flank A3243G
5 HRAS p.Q61R CDKN2C p.D67N Loss of 22 MY-CYB missense mutation T15729C
6 BRAF p.K601E TET2 p.V1718L MCL1 p.E41A - MT-ND1 missense mutation c.G3901A
7 - NFE2L2 p.29_32del Gain of 9p MT-RNR1 5’flank G709A
8 - EZH1 p.Q571R - MT-ND4 frame shift deletion A11038-
9 - TSHR p.M453T Gain of 5, 10, 12, 17, 18, 20, 21, X; WCD of 7; Copy neutral LOH in 9 -
10 - - Gain of 5, 9, 12, 16, 20; WCD of 7; Copy neutral LOH in X -
11 - - Loss of 2p; balanced gain in 4 -
12 - - Gain of 4, 12, 18, 21; WCD of 7 MT-ND2 missense mutation T5412C
13 - - - MT-ND4 nonsense mutation G11390A
14 - - - MT-ND4 frame shift insertion −10952C
15 - - - -

WCD: whole chromosome duplication, LOH: loss of heterozygosity. Frameshift or nonsense mutations in bold characters.